Clinical Trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Protocol Amendment History 3 changes
notable Trial sites expanded: 269 -> 286 locations 2026-07-02
notable Trial sites expanded: 258 -> 269 locations 2026-05-28
notable Trial sites expanded: 230 -> 258 locations 2026-04-14
Trial Details
NCT Number NCT07431281
Lead Sponsor AstraZeneca
Conditions Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Enrollment 2,130 participants
Start Date 2026-02-03
Primary Completion 2029-08-16 (estimated)
Study Completion 2031-10-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-01